1
|
Dobbs KR, Lobb A, Dent AE. Ebola virus disease in children: epidemiology, pathogenesis, management, and prevention. Pediatr Res 2024; 95:488-495. [PMID: 37903937 DOI: 10.1038/s41390-023-02873-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 10/06/2023] [Accepted: 10/12/2023] [Indexed: 11/01/2023]
Abstract
Ebola disease is a severe disease with extremely high case-fatality rates ranging from 28-100%. Observations made during the 2013-2016 West African epidemic improved our understanding of the clinical course of Ebola disease and accelerated the study of therapeutic and preventative strategies. The epidemic also highlighted the unique challenges associated with providing optimal care for children during Ebola disease outbreaks. In this review, we outline current understanding of Ebola disease epidemiology, pathogenesis, management, and prevention, highlighting data pertinent to the care of children. IMPACT: In this review, we summarize recent advancements in our understanding of Ebola disease epidemiology, clinical presentation, and therapeutic and preventative strategies. We highlight recent data pertinent to the care of children and pregnant women and identify research gaps for this important emerging viral infection in children.
Collapse
Affiliation(s)
- Katherine R Dobbs
- Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- UH Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
| | - Alyssa Lobb
- Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Arlene E Dent
- Case Western Reserve University School of Medicine, Cleveland, OH, USA
| |
Collapse
|
2
|
Mukadi-Bamuleka D, Nkuba-Ndaye A, Mbala-Kingebeni P, Ahuka-Mundeke S, Muyembe-Tamfum JJ. Impact of Ebola epidemics on the daily operation of existing systems in Eastern Democratic Republic of the Congo: a brief review. J Med Econ 2024; 27:184-192. [PMID: 38240249 DOI: 10.1080/13696998.2024.2305009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 01/10/2024] [Indexed: 01/23/2024]
Abstract
AIMS to provide insights into the recent Ebola virus disease (EVD) outbreaks on different aspects of daily life in the Democratic Republic of the Congo and propose possible solutions. METHODS We collected information regarding the effects of EVD outbreaks on existing systems in the eastern part of the Democratic Republic of the Congo (DRC). We searched the PubMed database using the terms "impact effect Ebola outbreak system", "Management Ebola Poor Resources Settings", "Health Economic Challenges Ebola" and "Economic impact Ebola systems." Only studies focusing on epidemiology, diagnostics, sequencing, vaccination, therapeutics, ecology, work force, governance, healthcare provision and health system, and social, political, and economic aspects were considered. The search included the electronic archives of EVD outbreak reports from government and partners. RESULTS EVD outbreaks negatively impacts the functions of countries. The disruption in activities is proportional to the magnitude of the epidemic and slows down the transport of goods, decreases the region's tourist appeal, and increases 'brain drain'. Most low- and medium-income countries, such as the DRC, do not have a long-term holistic emergency plan for unexpected situations or sufficient resources to adequately implement countermeasures against EVD outbreaks. Although the DRC has acquired sufficient expertise in diagnostics, genomic sequencing, administration of vaccines and therapeutics, clinical trials, and research activities, deployment, operation, and maintenance of these expertise and associated tools remains a concern. LIMITATIONS Despite the data search extension, additional reports addressing issues related to social aspects of EVD outbreaks in DRC were not retrieved. CONCLUSION National leadership has not yet taken the lead in strategic, operational, or financial aspects. Therefore, national leaders should double their efforts and awareness to encourage local fundraising, sufficient budget al.location, infrastructure construction, equipment provision, and staff training, to effectively support a holistic approach in response to outbreaks, providing effective results, and all types of research activities.
Collapse
Affiliation(s)
- Daniel Mukadi-Bamuleka
- Department of Virology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
- Rodolphe Mérieux INRB-Goma Laboratory, Institut National de Recherche Biomédicale (INRB), Goma, Democratic Republic of the Congo
- Service of Microbiology, Department of Medical Biology, Kinshasa Teaching School of Medicine, University of Kinshasa, Democratic Republic of the Congo
| | - Antoine Nkuba-Ndaye
- Department of Virology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
- Service of Microbiology, Department of Medical Biology, Kinshasa Teaching School of Medicine, University of Kinshasa, Democratic Republic of the Congo
| | - Placide Mbala-Kingebeni
- Department of Virology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
- Service of Microbiology, Department of Medical Biology, Kinshasa Teaching School of Medicine, University of Kinshasa, Democratic Republic of the Congo
| | - Steve Ahuka-Mundeke
- Department of Virology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
- Service of Microbiology, Department of Medical Biology, Kinshasa Teaching School of Medicine, University of Kinshasa, Democratic Republic of the Congo
| | - Jean-Jacques Muyembe-Tamfum
- Department of Virology, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo
- Service of Microbiology, Department of Medical Biology, Kinshasa Teaching School of Medicine, University of Kinshasa, Democratic Republic of the Congo
| |
Collapse
|
3
|
Zola Matuvanga T, Mariën J, Larivière Y, Osang’ir BI, Milolo S, Meta R, Esanga E, Maketa V, Matangila J, Mitashi P, Ahuka Mundeke S, Muhindo-Mavoko H, Muyembe Tamfum JJ, Van Damme P, Van Geertruyden JP. Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo. PLoS One 2023; 18:e0286479. [PMID: 37656725 PMCID: PMC10473486 DOI: 10.1371/journal.pone.0286479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 05/16/2023] [Indexed: 09/03/2023] Open
Abstract
INTRODUCTION A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. METHODS Serum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. RESULTS The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7-2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0-1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA. CONCLUSION In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.
Collapse
Affiliation(s)
- Trésor Zola Matuvanga
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo
- Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Antwerp, Belgium
- Department of Family Medicine and Population Health, Global Health Institute, University of Antwerp, Wilrijk, Antwerp, Belgium
| | - Joachim Mariën
- Department of Biology, Evolutionary Ecology Group, University of Antwerp, Wilrijk, Antwerp, Belgium
| | - Ynke Larivière
- Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Antwerp, Belgium
- Department of Family Medicine and Population Health, Global Health Institute, University of Antwerp, Wilrijk, Antwerp, Belgium
| | - Bernard Isekah Osang’ir
- Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Antwerp, Belgium
- Department of Family Medicine and Population Health, Global Health Institute, University of Antwerp, Wilrijk, Antwerp, Belgium
| | - Solange Milolo
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Rachel Meta
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Emmanuel Esanga
- Division Provinciale de la Santé de la Tshuapa, Ministry of Health Hygiene and Prevention, Boende, Tshuapa, Democratic Republic of the Congo
| | - Vivi Maketa
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Junior Matangila
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Patrick Mitashi
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Steve Ahuka Mundeke
- Department of Virology, Institut National de Recherches Biomedicales, Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Hypolite Muhindo-Mavoko
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Jean-Jacques Muyembe Tamfum
- Department of Virology, Institut National de Recherches Biomedicales, Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Pierre Van Damme
- Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Antwerp, Belgium
| | - Jean-Pierre Van Geertruyden
- Department of Family Medicine and Population Health, Global Health Institute, University of Antwerp, Wilrijk, Antwerp, Belgium
| |
Collapse
|
4
|
Jain S, Khaiboullina S, Martynova E, Morzunov S, Baranwal M. Epidemiology of Ebolaviruses from an Etiological Perspective. Pathogens 2023; 12:pathogens12020248. [PMID: 36839520 PMCID: PMC9963726 DOI: 10.3390/pathogens12020248] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Revised: 01/21/2023] [Accepted: 01/29/2023] [Indexed: 02/05/2023] Open
Abstract
Since the inception of the ebolavirus in 1976, 32 outbreaks have resulted in nearly 15,350 deaths in more than ten countries of the African continent. In the last decade, the largest (2013-2016) and second largest (2018-2020) ebolavirus outbreaks have occurred in West Africa (mainly Guinea, Liberia, and Sierra Leone) and the Democratic Republic of the Congo, respectively. The 2013-2016 outbreak indicated an alarming geographical spread of the virus and was the first to qualify as an epidemic. Hence, it is imperative to halt ebolavirus progression and develop effective countermeasures. Despite several research efforts, ebolaviruses' natural hosts and secondary reservoirs still elude the scientific world. The primary source responsible for infecting the index case is also unknown for most outbreaks. In this review, we summarize the history of ebolavirus outbreaks with a focus on etiology, natural hosts, zoonotic reservoirs, and transmission mechanisms. We also discuss the reasons why the African continent is the most affected region and identify steps to contain this virus.
Collapse
Affiliation(s)
- Sahil Jain
- Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala 147004, Punjab, India
- Department of Biochemistry and Molecular Biology, Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv 6997801, Israel
| | - Svetlana Khaiboullina
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Tatarstan, Russia
| | - Ekaterina Martynova
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Tatarstan, Russia
| | - Sergey Morzunov
- Department of Pathology, School of Medicine, University of Nevada, Reno, NV 89557, USA
- Correspondence: (S.M.); or (M.B.); Tel.: +1-775-682-6230 (S.M.); +91-175-2393118 (M.B.); Fax: +91-175-2364498 (M.B.)
| | - Manoj Baranwal
- Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala 147004, Punjab, India
- Correspondence: (S.M.); or (M.B.); Tel.: +1-775-682-6230 (S.M.); +91-175-2393118 (M.B.); Fax: +91-175-2364498 (M.B.)
| |
Collapse
|
5
|
Veron G, Daniel C, Pagani P, Do Linh San E, Kitchener AC, Hassanin A. A tale of two African mongooses (Carnivora: Herpestidae): differing genetic diversity and geographical structure across a continent. Mamm Biol 2022. [DOI: 10.1007/s42991-022-00321-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
6
|
Stephens PR, Sundaram M, Ferreira S, Gottdenker N, Nipa KF, Schatz AM, Schmidt JP, Drake JM. Drivers of African Filovirus (Ebola and Marburg) Outbreaks. Vector Borne Zoonotic Dis 2022; 22:478-490. [PMID: 36084314 PMCID: PMC9508452 DOI: 10.1089/vbz.2022.0020] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Outbreaks of African filoviruses often have high mortality, including more than 11,000 deaths among 28,562 cases during the West Africa Ebola outbreak of 2014-2016. Numerous studies have investigated the factors that contributed to individual filovirus outbreaks, but there has been little quantitative synthesis of this work. In addition, the ways in which the typical causes of filovirus outbreaks differ from other zoonoses remain poorly described. In this study, we quantify factors associated with 45 outbreaks of African filoviruses (ebolaviruses and Marburg virus) using a rubric of 48 candidate causal drivers. For filovirus outbreaks, we reviewed >700 peer-reviewed and gray literature sources and developed a list of the factors reported to contribute to each outbreak (i.e., a "driver profile" for each outbreak). We compare and contrast the profiles of filovirus outbreaks to 200 background outbreaks, randomly selected from a global database of 4463 outbreaks of bacterial and viral zoonotic diseases. We also test whether the quantitative patterns that we observed were robust to the influences of six covariates, country-level factors such as gross domestic product, population density, and latitude that have been shown to bias global outbreak data. We find that, regardless of whether covariates are included or excluded from models, the driver profile of filovirus outbreaks differs from that of background outbreaks. Socioeconomic factors such as trade and travel, wild game consumption, failures of medical procedures, and deficiencies in human health infrastructure were more frequently reported in filovirus outbreaks than in the comparison group. Based on our results, we also present a review of drivers reported in at least 10% of filovirus outbreaks, with examples of each provided.
Collapse
Affiliation(s)
- Patrick R. Stephens
- Department of Integrative Biology, Oklahoma State University, Stillwater, Oklahoma, USA
| | - Mekala Sundaram
- Department of Integrative Biology, Oklahoma State University, Stillwater, Oklahoma, USA
| | - Susana Ferreira
- Center for the Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, USA
- Department of Agricultural and Applied Economics, University of Georgia, Athens, Georgia, USA
| | - Nicole Gottdenker
- Center for the Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, USA
- Department of Agricultural and Applied Economics, University of Georgia, Athens, Georgia, USA
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA
- Odum School of Ecology, University of Georgia, Athens, Georgia, USA
| | - Kaniz Fatema Nipa
- Center for the Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, USA
- Odum School of Ecology, University of Georgia, Athens, Georgia, USA
| | - Annakate M. Schatz
- Center for the Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, USA
- Odum School of Ecology, University of Georgia, Athens, Georgia, USA
| | - John Paul Schmidt
- Center for the Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, USA
- Odum School of Ecology, University of Georgia, Athens, Georgia, USA
| | - John M. Drake
- Center for the Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, USA
- Odum School of Ecology, University of Georgia, Athens, Georgia, USA
| |
Collapse
|
7
|
Seifert SN, Fischer RJ, Kuisma E, Badzi Nkoua C, Bounga G, Akongo MJ, Schulz JE, Escudero-Pérez B, Akoundzie BJ, Ampiri VRB, Dieudonne A, Indolo GD, Kaba SD, Louzolo I, Macosso LN, Mavoungou Y, Miegakanda VBB, Nina RA, Samabide KT, Ondzie AI, Ntoumi F, Muñoz-Fontela C, Mombouli JV, Olson SH, Walzer C, Niama FR, Munster VJ. Zaire ebolavirus surveillance near the Bikoro region of the Democratic Republic of the Congo during the 2018 outbreak reveals presence of seropositive bats. PLoS Negl Trop Dis 2022; 16:e0010504. [PMID: 35731800 PMCID: PMC9255767 DOI: 10.1371/journal.pntd.0010504] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Revised: 07/05/2022] [Accepted: 05/16/2022] [Indexed: 11/18/2022] Open
Abstract
On the 8th of May, 2018, an outbreak of Ebola virus disease (EVD) was declared, originating in the Bikoro region of the Democratic Republic of the Congo (DRC) near the border with neighboring Republic of the Congo (ROC). Frequent trade and migration occur between DRC and ROC-based communities residing along the Congo River. In June 2018, a field team was deployed to determine whether Zaire ebolavirus (Ebola virus (EBOV)) was contemporaneously circulating in local bats at the human-animal interface in ROC near the Bikoro EVD outbreak. Samples were collected from bats in the Cuvette and Likouala departments, ROC, bordering the Équateur Province in DRC where the Bikoro EVD outbreak was first detected. EBOV genomic material was not detected in bat-derived samples by targeted quantitative reverse transcription-polymerase chain reaction or by family-level consensus polymerase chain reaction; however, serological data suggests recent exposure to EBOV in bats in the region. We collected serum from 144 bats in the Cuvette department with 6.9% seropositivity against the EBOV glycoprotein and 14.3% seropositivity for serum collected from 27 fruit bats and one Molossinae in the Likouala department. We conclude that proactive investment in longitudinal sampling for filoviruses at the human-animal interface, coupled with ecological investigations are needed to identify EBOV wildlife reservoirs.
Collapse
Affiliation(s)
- Stephanie N. Seifert
- Paul G. Allen School for Global Health, College of Veterinary Medicine, Washington State University, Pullman, Washington, United States
- Virus Ecology Section, Laboratory of Virology, Rocky Mountain Laboratories, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States
- * E-mail:
| | - Robert J. Fischer
- Virus Ecology Section, Laboratory of Virology, Rocky Mountain Laboratories, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States
| | - Eeva Kuisma
- Wildlife Health Program, Wildlife Conservation Society, Brazzaville, Republic of the Congo
| | - Cynthia Badzi Nkoua
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Gerard Bounga
- Wildlife Health Program, Wildlife Conservation Society, Brazzaville, Republic of the Congo
| | - Marc-Joël Akongo
- Wildlife Health Program, Wildlife Conservation Society, Brazzaville, Republic of the Congo
| | - Jonathan E. Schulz
- Virus Ecology Section, Laboratory of Virology, Rocky Mountain Laboratories, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States
| | - Beatriz Escudero-Pérez
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research (DZIF), Partner Site Hamburg-Luebeck-Borstel, Germany
| | - Beal-Junior Akoundzie
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Vishnou Reize Bani Ampiri
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Ankara Dieudonne
- Direction de la Santé Animale, Ministére de L’Agriculture et de L’Élevage, Brazzaville, Republic of the Congo
| | - Ghislain Dzeret Indolo
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Serge D. Kaba
- Wildlife Health Program, Wildlife Conservation Society, Brazzaville, Republic of the Congo
| | - Igor Louzolo
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Lucette Nathalie Macosso
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Yanne Mavoungou
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Valchy Bel-bebi Miegakanda
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Rock Aimé Nina
- Direction de la Santé Animale, Ministére de L’Agriculture et de L’Élevage, Brazzaville, Republic of the Congo
| | - Kevin Tolovou Samabide
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
- Faculty of Sciences and Techniques, Université Marien N’Gouabi, Brazzaville, Republic of the Congo
| | - Alain I. Ondzie
- Wildlife Health Program, Wildlife Conservation Society, Brazzaville, Republic of the Congo
| | - Francine Ntoumi
- Faculty of Sciences and Techniques, Université Marien N’Gouabi, Brazzaville, Republic of the Congo
- Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of the Congo
- Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany
| | | | - Jean-Vivien Mombouli
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Sarah H. Olson
- Health Program, Wildlife Conservation Society, New York, New York, United States
| | - Chris Walzer
- Health Program, Wildlife Conservation Society, New York, New York, United States
- Research Institute of Wildlife Ecology, University of Veterinary Medicine, Vienna, Austria
| | - Fabien Roch Niama
- Département de la Recherche et de la Production, Laboratoire National de Santé Publique, Brazzaville, Republic of the Congo
| | - Vincent J. Munster
- Virus Ecology Section, Laboratory of Virology, Rocky Mountain Laboratories, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States
| |
Collapse
|
8
|
Kemenesi G, Tóth GE, Mayora-Neto M, Scott S, Temperton N, Wright E, Mühlberger E, Hume AJ, Suder EL, Zana B, Boldogh SA, Görföl T, Estók P, Lanszki Z, Somogyi BA, Nagy Á, Pereszlényi CI, Dudás G, Földes F, Kurucz K, Madai M, Zeghbib S, Maes P, Vanmechelen B, Jakab F. Isolation of infectious Lloviu virus from Schreiber's bats in Hungary. Nat Commun 2022; 13:1706. [PMID: 35361761 PMCID: PMC8971391 DOI: 10.1038/s41467-022-29298-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 03/08/2022] [Indexed: 11/09/2022] Open
Abstract
Some filoviruses can be transmitted to humans by zoonotic spillover events from their natural host and filovirus outbreaks have occured with increasing frequency in the last years. The filovirus Lloviu virus (LLOV), was identified in 2002 in Schreiber’s bats (Miniopterus schreibersii) in Spain and was subsequently detected in bats in Hungary. Here we isolate infectious LLOV from the blood of a live sampled Schreiber’s bat in Hungary. The isolate is subsequently sequenced and cultured in the Miniopterus sp. kidney cell line SuBK12-08. It is furthermore able to infect monkey and human cells, suggesting that LLOV might have spillover potential. A multi-year surveillance of LLOV in bats in Hungary detects LLOV RNA in both deceased and live animals as well as in coupled ectoparasites from the families Nycteribiidae and Ixodidae. This correlates with LLOV seropositivity in sampled Schreiber’s bats. Our data support the role of bats, specifically Miniopterus schreibersii as hosts for LLOV in Europe. We suggest that bat-associated parasites might play a role in the natural ecology of filoviruses in temperate climate regions compared to filoviruses in the tropics. Lloviu virus (LLOV) is a filovirus that was first identified in 2002 in Schreiber’s bats in Europe. Here, the authors isolate infectious LLOV from Schreiber’s bats in Hungary and show that it can infect human cells in vitro, suggesting potential for zoonotic events. They furthermore detect LLOV RNA in ectoparasites of sampled bats.
Collapse
Affiliation(s)
- Gábor Kemenesi
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary. .,Institute of Biology, Faculty of Sciences, University of Pécs, Pécs, Hungary.
| | - Gábor E Tóth
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary.,Institute of Biology, Faculty of Sciences, University of Pécs, Pécs, Hungary
| | - Martin Mayora-Neto
- Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Universities of Kent & Greenwich, Kent, UK
| | - Simon Scott
- Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Universities of Kent & Greenwich, Kent, UK
| | - Nigel Temperton
- Viral Pseudotype Unit, Medway School of Pharmacy, Chatham Maritime, Universities of Kent & Greenwich, Kent, UK
| | - Edward Wright
- Viral Pseudotype Unit, School of Life Sciences, University of Sussex, Falmer, Sussex, UK
| | - Elke Mühlberger
- Department of Microbiology, Boston University School of Medicine, Boston, MA, USA
| | - Adam J Hume
- Department of Microbiology, Boston University School of Medicine, Boston, MA, USA
| | - Ellen L Suder
- Department of Microbiology, Boston University School of Medicine, Boston, MA, USA
| | - Brigitta Zana
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | | | - Tamás Görföl
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Péter Estók
- Department of Zoology, Eszterházy Károly University, Eger, Hungary
| | - Zsófia Lanszki
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary.,Institute of Biology, Faculty of Sciences, University of Pécs, Pécs, Hungary
| | - Balázs A Somogyi
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Ágnes Nagy
- Medical Centre, Hungarian Defence Forces, Budapest, Hungary
| | | | - Gábor Dudás
- Medical Centre, Hungarian Defence Forces, Budapest, Hungary
| | - Fanni Földes
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Kornélia Kurucz
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary.,Institute of Biology, Faculty of Sciences, University of Pécs, Pécs, Hungary
| | - Mónika Madai
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Safia Zeghbib
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Piet Maes
- Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Leuven, Belgium
| | - Bert Vanmechelen
- Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Leuven, Belgium
| | - Ferenc Jakab
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary.,Institute of Biology, Faculty of Sciences, University of Pécs, Pécs, Hungary
| |
Collapse
|
9
|
Stephens PR, Gottdenker N, Schatz AM, Schmidt JP, Drake JM. Characteristics of the 100 largest modern zoonotic disease outbreaks. Philos Trans R Soc Lond B Biol Sci 2021; 376:20200535. [PMID: 34538141 PMCID: PMC8450623 DOI: 10.1098/rstb.2020.0535] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/14/2021] [Indexed: 12/19/2022] Open
Abstract
Zoonotic disease outbreaks are an important threat to human health and numerous drivers have been recognized as contributing to their increasing frequency. Identifying and quantifying relationships between drivers of zoonotic disease outbreaks and outbreak severity is critical to developing targeted zoonotic disease surveillance and outbreak prevention strategies. However, quantitative studies of outbreak drivers on a global scale are lacking. Attributes of countries such as press freedom, surveillance capabilities and latitude also bias global outbreak data. To illustrate these issues, we review the characteristics of the 100 largest outbreaks in a global dataset (n = 4463 bacterial and viral zoonotic outbreaks), and compare them with 200 randomly chosen background controls. Large outbreaks tended to have more drivers than background outbreaks and were related to large-scale environmental and demographic factors such as changes in vector abundance, human population density, unusual weather conditions and water contamination. Pathogens of large outbreaks were more likely to be viral and vector-borne than background outbreaks. Overall, our case study shows that the characteristics of large zoonotic outbreaks with thousands to millions of cases differ consistently from those of more typical outbreaks. We also discuss the limitations of our work, hoping to pave the way for more comprehensive future studies. This article is part of the theme issue 'Infectious disease macroecology: parasite diversity and dynamics across the globe'.
Collapse
Affiliation(s)
- Patrick R. Stephens
- Odum School of Ecology and Center for the Ecology of Infectious Diseases, University of Georgia, Athens, 30602 GA, USA
| | - N. Gottdenker
- Odum School of Ecology and Center for the Ecology of Infectious Diseases, University of Georgia, Athens, 30602 GA, USA
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, 30602 GA, USA
| | - A. M. Schatz
- Odum School of Ecology and Center for the Ecology of Infectious Diseases, University of Georgia, Athens, 30602 GA, USA
| | - J. P. Schmidt
- Odum School of Ecology and Center for the Ecology of Infectious Diseases, University of Georgia, Athens, 30602 GA, USA
| | - John M. Drake
- Odum School of Ecology and Center for the Ecology of Infectious Diseases, University of Georgia, Athens, 30602 GA, USA
| |
Collapse
|
10
|
Bokelmann M, Vogel U, Debeljak F, Düx A, Riesle-Sbarbaro S, Lander A, Wahlbrink A, Kromarek N, Neil S, Couacy-Hymann E, Prescott J, Kurth A. Tolerance and Persistence of Ebola Virus in Primary Cells from Mops condylurus, a Potential Ebola Virus Reservoir. Viruses 2021; 13:v13112186. [PMID: 34834992 PMCID: PMC8622823 DOI: 10.3390/v13112186] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 10/14/2021] [Accepted: 10/26/2021] [Indexed: 11/16/2022] Open
Abstract
Although there have been documented Ebola virus disease outbreaks for more than 40 years, the natural reservoir host has not been identified. Recent studies provide evidence that the Angolan free-tailed bat (Mops condylurus), an insectivorous microbat, is a possible ebolavirus reservoir. To investigate the potential role of this bat species in the ecology of ebolaviruses, replication, tolerance, and persistence of Ebola virus (EBOV) were investigated in 10 different primary bat cell isolates from M. condylurus. Varying EBOV replication kinetics corresponded to the expression levels of the integral membrane protein NPC1. All primary cells were highly tolerant to EBOV infection without cytopathic effects. The observed persistent EBOV infection for 150 days in lung primary cells, without resultant selective pressure leading to virus mutation, indicate the intrinsic ability of EBOV to persist in this bat species. These results provide further evidence for this bat species to be a likely reservoir of ebolaviruses.
Collapse
Affiliation(s)
- Marcel Bokelmann
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Uwe Vogel
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Franka Debeljak
- Department of Infectious Diseases, King’s College London, London WC2R 2LS, UK; (F.D.); (S.N.)
| | - Ariane Düx
- Epidemiology of Highly Pathogenic Microorganisms, Robert Koch Institute, 13353 Berlin, Germany;
| | - Silke Riesle-Sbarbaro
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Angelika Lander
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Annette Wahlbrink
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Nicole Kromarek
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Stuart Neil
- Department of Infectious Diseases, King’s College London, London WC2R 2LS, UK; (F.D.); (S.N.)
| | - Emmanuel Couacy-Hymann
- Laboratoire National d’Appui au Développement Agricole, Bingerville BP 206, Côte d’Ivoire;
| | - Joseph Prescott
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Andreas Kurth
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
- Correspondence:
| |
Collapse
|
11
|
Larivière Y, Zola T, Stoppie E, Maketa V, Matangila J, Mitashi P, De Bie J, Muhindo-Mavoko H, Van Geertruyden JP, Van Damme P. Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol. BMJ Open 2021; 11:e046835. [PMID: 34588237 PMCID: PMC8479954 DOI: 10.1136/bmjopen-2020-046835] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
INTRODUCTION This article describes the protocol of an Ebola vaccine clinical trial which investigates the safety and immunogenicity of a two-dose prophylactic Ebola vaccine regimen comprised of two Ebola vaccines (Ad26.ZEBOV and MVA-BN-Filo) administered 56 days apart, followed by a booster vaccination with Ad26.ZEBOV offered at either 1 year or 2 years (randomisation 1:1) after the first dose. This clinical trial is part of the EBOVAC3 project (an Innovative Medicines Initiative 2 Joint Undertaking), and is the first to evaluate the safety and immunogenicity of two different booster vaccination arms in a large cohort of adults. METHODS AND ANALYSIS This study is an open-label, monocentric, phase 2, randomised vaccine trial. A total of 700 healthcare providers and frontliners are planned to be recruited from the Tshuapa province in the Democratic Republic of the Congo (DRC). The primary and secondary objectives of the study assess the immunogenicity of the first (Ad26.ZEBOV), second (MVA-BN-Filo) and booster (Ad26.ZEBOV) dose. Immunogenicity is assessed through the evaluation of EBOV glycoprotein binding antibody responses after vaccination. Safety is assessed through the collection of serious adverse events from the first dose until 6 months post booster vaccination and the collection of solicited and unsolicited adverse events for 1 week after the booster dose. ETHICS AND DISSEMINATION The protocol was approved by the National Ethics Committee of the Ministry of Health of the DRC (n°121/CNES/BN/PMMF/2019). The clinical trial was registered on 4 December 2019 on ClinicalTrials.gov. Trial activities are planned to finish in October 2022. All participants are required to provide written informed consent and no study-related procedures will be performed until consent is obtained. The results of the trial will be added on ClinicalTrials.gov, published in peer-reviewed journals and presented at international conferences. TRIAL REGISTRATION NUMBER NCT04186000; Pre-results.
Collapse
Affiliation(s)
- Ynke Larivière
- Centre for Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium
- Global Health Institute, University of Antwerp, Wilrijk, Belgium
| | - Trésor Zola
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)
| | - Elke Stoppie
- Centre for Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium
- Global Health Institute, University of Antwerp, Wilrijk, Belgium
| | - Vivi Maketa
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)
| | - Junior Matangila
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)
| | - Patrick Mitashi
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)
| | - Jessie De Bie
- Centre for Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium
- Global Health Institute, University of Antwerp, Wilrijk, Belgium
| | - Hypolite Muhindo-Mavoko
- Tropical Medicine Department, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)
| | | | - Pierre Van Damme
- Centre for Evaluation of Vaccination, University of Antwerp, Wilrijk, Belgium
| |
Collapse
|
12
|
Simo Tchetgna H, Descorps-Declère S, Selekon B, Kwasiborski A, Vandenbogaert M, Manuguerra JC, Gessain A, Caro V, Nakouné E, Berthet N. Molecular characterization of a new highly divergent Mobala related arenavirus isolated from Praomys sp. rodents. Sci Rep 2021; 11:10188. [PMID: 33986310 PMCID: PMC8119949 DOI: 10.1038/s41598-021-88046-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Accepted: 04/06/2021] [Indexed: 12/02/2022] Open
Abstract
Arenaviruses represent a family of viruses that are naturally present in rodents belonging to subfamily Murinae, Neotominae or Sigmodontinae. Except for Lassa virus, little information is available on other Old-World arenaviruses. Here, we describe strain AnRB3214, a virus isolated from a presumed Praomys sp. rodent in the Central African Republic in 1981 and assigned to Ippy virus based on antigenic similarity. The strain was simultaneously sequenced on Illumina NovaSeq 6000 and MinION Mk1B devices and analysed with various bioinformatics tools. We show that the best genome coverage and depth were obtained with the Kaiju and Minimap2 classification and identification tools, on either the MinION or the Illumina reads. The genetic analysis of AnRB3214 fragments showed 68% to 79% similarity with the Mobala and Gairo mammarenaviruses at the nucleic acid level. Strain AnRB3214 had a truncated nucleoprotein smaller than that of other Old World arenaviruses. Molecular clock analysis suggests that this strain diverged from Mobala virus at least 400 years ago. Finally, this study illustrates the importance of genomics in the identification of archived viruses and expands on the diversity of African arenaviruses, because strain AnRB3214 is either a variant or a close relative of Mobala virus, and not Ippy virus.
Collapse
Affiliation(s)
- Huguette Simo Tchetgna
- Centre for Research in Infectious Diseases, Yaoundé, Cameroon.,The Center for Microbes, Development and Health, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai - Chinese Academy of Sciences, Discovery and Molecular Characterization of Pathogens, Shanghai, 200031, China
| | - Stephane Descorps-Declère
- Center of Bioinformatics, Biostatistics and Integrative Biology (C3BI), Institut Pasteur, Paris, France
| | | | - Aurelia Kwasiborski
- Cellule d'Intervention Biologique d'Urgence, Institut Pasteur, Unité Environnement et Risques Infectieux, Paris, France
| | - Mathias Vandenbogaert
- Cellule d'Intervention Biologique d'Urgence, Institut Pasteur, Unité Environnement et Risques Infectieux, Paris, France
| | - Jean-Claude Manuguerra
- Cellule d'Intervention Biologique d'Urgence, Institut Pasteur, Unité Environnement et Risques Infectieux, Paris, France
| | - Antoine Gessain
- Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur, Paris, France.,Centre National de Recherche Scientifique (CNRS) UMR3569, Paris, France
| | - Valérie Caro
- Cellule d'Intervention Biologique d'Urgence, Institut Pasteur, Unité Environnement et Risques Infectieux, Paris, France
| | | | - Nicolas Berthet
- The Center for Microbes, Development and Health, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai - Chinese Academy of Sciences, Discovery and Molecular Characterization of Pathogens, Shanghai, 200031, China. .,Cellule d'Intervention Biologique d'Urgence, Institut Pasteur, Unité Environnement et Risques Infectieux, Paris, France.
| |
Collapse
|
13
|
Lacroix A, Mbala Kingebeni P, Ndimbo Kumugo SP, Lempu G, Butel C, Serrano L, Vidal N, Thaurignac G, Esteban A, Mukadi Bamuleka D, Likofata J, Delaporte E, Muyembe Tamfum JJ, Ayouba A, Peeters M, Ahuka Mundeke S. Investigating the Circulation of Ebola Viruses in Bats during the Ebola Virus Disease Outbreaks in the Equateur and North Kivu Provinces of the Democratic Republic of Congo from 2018. Pathogens 2021; 10:pathogens10050557. [PMID: 34064424 PMCID: PMC8147758 DOI: 10.3390/pathogens10050557] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 04/28/2021] [Accepted: 04/30/2021] [Indexed: 02/04/2023] Open
Abstract
With 12 of the 31 outbreaks, the Democratic Republic of Congo (DRC) is highly affected by Ebolavirus disease (EVD). To better understand the role of bats in the ecology of Ebola viruses, we conducted surveys in bats during two recent EVD outbreaks and in two areas with previous outbreaks. Dried blood spots were tested for antibodies to ebolaviruses and oral and rectal swabs were screened for the presence of filovirus using a broadly reactive semi-nested RT-PCR. Between 2018 and 2020, 892 (88.6%) frugivorous and 115 (11.4%) insectivorous bats were collected. Overall, 11/925 (1.2%) to 100/925 (10.8%) bats showed antibodies to at least one Ebolavirus antigen depending on the positivity criteria. Antibodies were detected in fruit bats from the four sites and from species previously documented to harbor Ebola antibodies or RNA. We tested for the first time a large number of bats during ongoing EVD outbreaks in DRC, but no viral RNA was detected in the 676 sampled bats. Our study illustrates the difficulty to document the role of bats as a source of Ebolaviruses as they might clear quickly the virus. Given the increasing frequency of EVD outbreaks, more studies on the animal reservoir are urgently needed.
Collapse
Affiliation(s)
- Audrey Lacroix
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
| | - Placide Mbala Kingebeni
- Institut National de Recherche Biomédicale (INRB), 1197 Kinshasa, Democratic Republic of the Congo; (P.M.K.); (S.P.N.K.); (G.L.); (J.-J.M.T.)
- Service de Microbiologie, Cliniques Universitaires de Kinshasa, 1197 Kinshasa, Democratic Republic of the Congo;
| | - Simon Pierre Ndimbo Kumugo
- Institut National de Recherche Biomédicale (INRB), 1197 Kinshasa, Democratic Republic of the Congo; (P.M.K.); (S.P.N.K.); (G.L.); (J.-J.M.T.)
| | - Guy Lempu
- Institut National de Recherche Biomédicale (INRB), 1197 Kinshasa, Democratic Republic of the Congo; (P.M.K.); (S.P.N.K.); (G.L.); (J.-J.M.T.)
| | - Christelle Butel
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
| | - Laetitia Serrano
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
| | - Nicole Vidal
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
| | - Guillaume Thaurignac
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
| | - Amandine Esteban
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
| | - Daniel Mukadi Bamuleka
- Service de Microbiologie, Cliniques Universitaires de Kinshasa, 1197 Kinshasa, Democratic Republic of the Congo;
- Institut National de Recherche Biomédicale (INRB), Goma, Democratic Republic of the Congo
| | - Jacques Likofata
- Laboratoire Provincial de Mbandaka, Equateur, Democratic Republic of the Congo;
| | - Eric Delaporte
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
| | - Jean-Jacques Muyembe Tamfum
- Institut National de Recherche Biomédicale (INRB), 1197 Kinshasa, Democratic Republic of the Congo; (P.M.K.); (S.P.N.K.); (G.L.); (J.-J.M.T.)
- Service de Microbiologie, Cliniques Universitaires de Kinshasa, 1197 Kinshasa, Democratic Republic of the Congo;
| | - Ahidjo Ayouba
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
| | - Martine Peeters
- TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de Montpellier, Institut de Recherche pour le Développement, INSERM, 34394 Montpellier, France; (A.L.); (C.B.); (L.S.); (N.V.); (G.T.); (A.E.); (E.D.); (A.A.)
- Correspondence: (M.P.); (S.A.M.)
| | - Steve Ahuka Mundeke
- Institut National de Recherche Biomédicale (INRB), 1197 Kinshasa, Democratic Republic of the Congo; (P.M.K.); (S.P.N.K.); (G.L.); (J.-J.M.T.)
- Service de Microbiologie, Cliniques Universitaires de Kinshasa, 1197 Kinshasa, Democratic Republic of the Congo;
- Correspondence: (M.P.); (S.A.M.)
| |
Collapse
|
14
|
Abstract
Efforts to produce vaccines against SARS and MERS were prematurely halted since their scope was perceived to be geographically restricted and they were subsequently categorized as neglected diseases. However, when a similar virus spread globally triggering the COVID-19 pandemic, we were harshly reminded that several other neglected diseases might also be waiting for the perfect opportunity to become mainstream. As climate change drives urbanization, natural selection of pathogens and their intermediate vectors and reservoirs, the risk of neglected diseases emerging within a larger susceptible pool becomes an even greater threat. Availability of a vaccine for COVID-19 is widely considered the only way to end this pandemic. Similarly, vaccines are also seen as the best tools available to control the spread of neglected (sometimes referred to as emerging or re-emerging) diseases, until the water, hygiene and sanitation infrastructure is improved in areas of their prevalence. Vaccine production is usually cost and labour intensive and thus minimal funding is directed towards controlling and eliminating neglected diseases (NDs). A customised but sustainable approach is needed to develop and deploy vaccines against NDs. While safety, efficacy and public trust are the three main success pillars for most vaccines, affordability is vital when formulating vaccines for neglected diseases.
Collapse
|